DUBLIN–(BUSINESS WIRE)–The “Crohn’s Disease (CD) – Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering.
This “Crohn’s Disease (CD)- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Crohn’s Disease (CD), historical and forecasted epidemiology as well as the Crohn’s Disease (CD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Crohn’s Disease (CD) market report provides current treatment practices, emerging drugs, Crohn’s Disease (CD) market share of the individual therapies, current and forecasted Crohn’s Disease (CD) market Size from 2019 to 2032 segmented by seven major markets.
The Report also covers current Crohn’s Disease (CD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Crohn’s Disease (CD) Disease Understanding and Treatment Algorithm
The Crohn’s Disease (CD) market report gives a thorough understanding of the Crohn’s Disease (CD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Crohn’s Disease (CD).
Treatment
It covers the details of conventional and current medical therapies available in the Crohn’s Disease (CD) market for the treatment of the condition. It also provides Crohn’s Disease (CD) treatment algorithms and guidelines in the United States, Europe, and Japan.
Crohn’s Disease (CD) Epidemiology
The Crohn’s Disease (CD) epidemiology division provide insights about historical and current Crohn’s Disease (CD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Report Highlights
- In the coming years, Crohn’s Disease (CD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Crohn’s Disease (CD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Crohn’s Disease (CD). Launch of emerging therapies will significantly impact the Crohn’s Disease (CD) market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Crohn’s Disease (CD)
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Key Topics Covered:
1. Key Insights
2. Executive Summary of Crohn’s Disease (CD)
3. Competitive Intelligence Analysis for Crohn’s Disease (CD)
4. Crohn’s Disease (CD): Market Overview at a Glance
4.1. Crohn’s Disease (CD) Total Market Share (%) Distribution in 2019
4.2. Crohn’s Disease (CD) Total Market Share (%) Distribution in 2032
5. Crohn’s Disease (CD): Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Crohn’s Disease (CD) Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Crohn’s Disease (CD) Epidemiology Scenario in the 7MM (2019-2032)
7.4. United States Epidemiology
7.4.1. Crohn’s Disease (CD) Epidemiology Scenario in the United States (2019-2032)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Crohn’s Disease (CD) Epidemiology Scenario in Germany (2019-2032)
7.5.2. France Epidemiology
7.5.3. Italy Epidemiology
7.5.4. Spain Epidemiology
7.5.5. United Kingdom Epidemiology
7.5.6. Japan Epidemiology
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Crohn’s Disease (CD) Treatment and Management
8.2. Crohn’s Disease (CD) Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Crohn’s Disease (CD) Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
13. Crohn’s Disease (CD): Seven Major Market Analysis
13.1. Key Findings
13.2. Crohn’s Disease (CD) Market Size in 7MM
13.3. Crohn’s Disease (CD) Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Crohn’s Disease (CD) Total Market Size in the United States
15.1.2. Crohn’s Disease (CD) Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.4. France Market Size
15.5. Italy Market Size
15.6. Spain Market Size
15.7. United Kingdom Market Size
15.8. Japan Market Outlook
16. Access and Reimbursement Overview of Crohn’s Disease (CD)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
Companies Mentioned
- AbbVie
- Arena Pharmaceuticals
- Astrazeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- Eli Lilly and Company
- Enterome
- Galapagos NV
- Genentech
- Gilead Sciences
- Hoffmann-La Roche
- Janssen
- Landos Biopharma
- Mesoblast
- Pfizer
- Protagonist Therapeutics
- RedHill Biopharma
- Reistone Biopharma
- Takeda
- Theravance Biopharma
- TiGenix
For more information about this report visit https://www.researchandmarkets.com/r/ebros5
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900